Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: A randomized phase II cardiac safety study (TRYPHAENA) (2013)
- Authors:
- Autor USP: HEGG, ROBERTO - FM
- Unidade: FM
- DOI: 10.1093/annonc/mdt182
- Subjects: NEOPLASIAS MAMÁRIAS (DIAGNÓSTICO;QUIMIOTERAPIA); ANTINEOPLÁSICOS (DIAGNÓSTICO)
- Language: Inglês
- Imprenta:
- Source:
- Título: Annals of Oncology
- ISSN: 0923-7534
- Volume/Número/Paginação/Ano: v. 24, n. 9, p. 2278-2284, 2013
- Este periódico é de assinatura
- Este artigo é de acesso aberto
- URL de acesso aberto
- Cor do Acesso Aberto: bronze
- Licença: publisher-specific-oa
-
ABNT
SCHNEEWEISS, A. et al. Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: A randomized phase II cardiac safety study (TRYPHAENA). Annals of Oncology, v. 24, n. 9, p. 2278-2284, 2013Tradução . . Disponível em: https://doi.org/10.1093/annonc/mdt182. Acesso em: 17 out. 2024. -
APA
Schneeweiss, A., Chia, S., Hickish, T., Harvey, V., Eniu, A., Hegg, R., et al. (2013). Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: A randomized phase II cardiac safety study (TRYPHAENA). Annals of Oncology, 24( 9), 2278-2284. doi:10.1093/annonc/mdt182 -
NLM
Schneeweiss A, Chia S, Hickish T, Harvey V, Eniu A, Hegg R, Tausch C, Seo JH, Tsai Y-F, Ratnayake J, McNally V, Ross G, Cortés J. Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: A randomized phase II cardiac safety study (TRYPHAENA) [Internet]. Annals of Oncology. 2013 ; 24( 9): 2278-2284.[citado 2024 out. 17 ] Available from: https://doi.org/10.1093/annonc/mdt182 -
Vancouver
Schneeweiss A, Chia S, Hickish T, Harvey V, Eniu A, Hegg R, Tausch C, Seo JH, Tsai Y-F, Ratnayake J, McNally V, Ross G, Cortés J. Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: A randomized phase II cardiac safety study (TRYPHAENA) [Internet]. Annals of Oncology. 2013 ; 24( 9): 2278-2284.[citado 2024 out. 17 ] Available from: https://doi.org/10.1093/annonc/mdt182 - Cancer de ovario
- Vias e esquemas de administração dos hormônios esteróides
- Eficácia, tolerabilidade e controle de ciclo de um contraceptivo oral sem estrogênio contendo 30 mcg de levonorgestrel (minipílula)
- Genetics of ramucirumab-associated hypertension in the ROSE/TRIO-012 breast cancer trial
- A phase 2 study of neoadjuvant goserelin and letrozole for premenopausal women with estrogen receptor positive HER2 negative stage 2 and 3 breast cancer
- First-line trastuzumab plus an aromatase inhibitor, with or without pertuzumab, in human epidermal growth factor Receptor 2-positive and hormone receptor-positive metastatic or locally advanced breast cancer (PERTAIN): a randomized, open-label phase II trial
- Distrofias vulvares
- Mastite puerperal
- Hormonioterapia de reposicao e cancer de mama
- Terapia estrogenica e cancer de mama
Informações sobre o DOI: 10.1093/annonc/mdt182 (Fonte: oaDOI API)
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas